Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06498128 · ClinicalTrials.gov registry record
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
A clinical trial of Insomnia, sponsored by Idorsia Pharmaceuticals.
- Recruiting
- Registry status
- 785
- Enrollment target
- 7
- Study locations
NCT06498128 is a study of Insomnia that is actively recruiting participants, run by Idorsia Pharmaceuticals. The registered enrollment target is 785 participants, above the 165-participant average among 151 other Insomnia trials with a reported enrollment target (376% higher). The trial reports 7 study locations across 3 states.
The verdict
NCT06498128, a study of Insomnia, is actively recruiting participants, sponsored by Idorsia Pharmaceuticals.
- RECRUITING
- Registry status
- 785 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.
Conditions Studied
Interventions
- DRUG Daridorexant
- DRUG Non-orexin receptor antagonist medications for insomnia
- OTHER No insomnia medication
Study Locations (7)
Other
- Hôpital Gui de Chauliac - Montpellier
- Charité - Universitätsmedizin Berlin - Berlin
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata - Rome
- Hospital Txagorritxu - Vitoria-Gasteiz
- University College London Hospitals - London
North Carolina
- IQVIA US Office - Durham
Ontario
- Jodha Tishon - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 785 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2033-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06498128
The ClinicalTrials.gov registry entry for NCT06498128 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 785 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 165-participant average among 151 other Insomnia trials with a reported enrollment target (376% higher). The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 3 interventions - of which Daridorexant is the first listed.
NCT06498128 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Other, North Carolina, Ontario.
Frequently Asked Questions
What is clinical trial NCT06498128 about?
NCT06498128 is a clinical study titled "Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®". This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.
What is the current status of trial NCT06498128?
This trial is currently recruiting. The enrollment target is 785 participants. The study started on 2024-11-21. Estimated completion is 2033-03.
What conditions does trial NCT06498128 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT06498128?
The interventions under investigation include: Daridorexant (DRUG), Non-orexin receptor antagonist medications for insomnia (DRUG), No insomnia medication (OTHER).
Who is sponsoring clinical trial NCT06498128?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06498128 being conducted?
This trial has 7 study locations across North Carolina, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Mindfulness Meditation for Insomnia
RECRUITING · Phase 1
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
mPATH for Low-income Older Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.